The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
As of close of business last night, Novavax, Inc.’s stock clocked out at $4.47, down -3.04% from its previous closing price of $4.61. In other words, the price has decreased by -$3.04 from its previous closing price. On the day, 3.07 million shares were traded. NVAX stock price reached its highest trading level at $4.5586 during the session, while it also had its lowest trading level at $4.43.
Ratios:
To gain a deeper understanding of NVAX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.67 and its Current Ratio is at 0.70.
On April 20, 2023, TD Cowen Downgraded its rating to Market Perform which previously was Outperform and also lowered its target price recommendation from $55 to $10.
B. Riley Securities Downgraded its Buy to Neutral on March 01, 2023, whereas the target price for the stock was revised from $29 to $10.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVAX now has a Market Capitalization of 627601408 and an Enterprise Value of 357313984. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.64. Its current Enterprise Value per Revenue stands at 0.363 whereas that against EBITDA is -0.699.
Stock Price History:
The Beta on a monthly basis for NVAX is 1.43, which has changed by -0.487208 over the last 52 weeks, in comparison to a change of 0.2537824 over the same period for the S&P500. Over the past 52 weeks, NVAX has reached a high of $11.36, while it has fallen to a 52-week low of $3.53. The 50-Day Moving Average of the stock is -4.72%, while the 200-Day Moving Average is calculated to be -23.78%.
Shares Statistics:
It appears that NVAX traded 6.91M shares on average per day over the past three months and 4151380 shares per day over the past ten days. A total of 139.51M shares are outstanding, with a floating share count of 133.41M. Insiders hold about 4.98% of the company’s shares, while institutions hold 58.03% stake in the company. Shares short for NVAX as of 1713139200 were 43769652 with a Short Ratio of 6.33, compared to 1710460800 on 48126414. Therefore, it implies a Short% of Shares Outstanding of 43769652 and a Short% of Float of 36.450002.
Earnings Estimates
As of right now, 5.0 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$1.06 for the current quarter, with a high estimate of -$0.85 and a low estimate of -$1.48, while EPS last year was -$3.41. The consensus estimate for the next quarter is -$0.85, with high estimates of -$0.53 and low estimates of -$1.23.
Analysts are recommending an EPS of between $0.13 and -$1.59 for the fiscal current year, implying an average EPS of -$0.72. EPS for the following year is -$0.04, with 6.0 analysts recommending between $1.66 and -$1.23.
Revenue Estimates
In the current quarter, 5 analysts expect revenue to total $101.16M. It ranges from a high estimate of $104M to a low estimate of $99.8M. As of the current estimate, Novavax, Inc.’s year-ago sales were $80.95M
A total of 6 analysts have provided revenue estimates for NVAX’s current fiscal year. The highest revenue estimate was $941.8M, while the lowest revenue estimate was $775M, resulting in an average revenue estimate of $845.49M. In the same quarter a year ago, actual revenue was $983.71MBased on 6 analysts’ estimates, the company’s revenue will be $986.48M in the next fiscal year. The high estimate is $1.61B and the low estimate is $635M.
